Insider Selling: Natera, Inc. (NASDAQ:NTRA) CEO Sells 3,960 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,960 shares of Natera stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $468,111.60. Following the transaction, the chief executive officer now directly owns 189,762 shares of the company’s stock, valued at approximately $22,431,766.02. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, October 21st, Steven Leonard Chapman sold 1,709 shares of Natera stock. The shares were sold at an average price of $120.76, for a total transaction of $206,378.84.
• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The stock was sold at an average price of $130.40, for a total transaction of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The stock was sold at an average price of $128.48, for a total value of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total value of $663,874.53.

Natera Stock Performance

Shares of NTRA stock opened at $120.96 on Friday. The stock has a market cap of $14.96 billion, a PE ratio of -49.37 and a beta of 1.53. The stock has a 50-day moving average of $123.40 and a 200-day moving average of $111.93. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera, Inc. has a one year low of $37.67 and a one year high of $133.54.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business’s quarterly revenue was up 58.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.97) earnings per share. As a group, sell-side analysts expect that Natera, Inc. will post -1.96 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Canaccord Genuity Group raised their target price on Natera from $145.00 to $150.00 and gave the company a “buy” rating in a research note on Tuesday. StockNews.com downgraded shares of Natera from a “hold” rating to a “sell” rating in a research note on Friday, October 25th. Piper Sandler reissued an “overweight” rating and set a $150.00 price target on shares of Natera in a research note on Friday, September 13th. UBS Group dropped their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Finally, Sanford C. Bernstein increased their price objective on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Natera has a consensus rating of “Moderate Buy” and an average target price of $125.69.

Institutional Trading of Natera

Several hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. acquired a new position in Natera in the second quarter valued at about $28,000. Quarry LP grew its position in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. GAMMA Investing LLC increased its stake in Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares in the last quarter. Tobam acquired a new stake in Natera during the 2nd quarter worth approximately $74,000. Finally, DekaBank Deutsche Girozentrale bought a new position in Natera in the first quarter valued at approximately $83,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.